Neovasc Executives
NVCNDelisted Stock | USD 30.03 0.00 0.00% |
Neovasc employs about 16 people. The company is managed by 16 executives with a total tenure of roughly 119 years, averaging almost 7.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Neovasc's management performance can provide insight into the firm performance.
Fred Colen CEO President CEO |
Alexei Marko CEO CEO and Non-Independent Director |
Neovasc |
Neovasc Management Team Effectiveness
The company has return on total asset (ROA) of (0.3295) % which means that it has lost $0.3295 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7825) %, meaning that it created substantial loss on money invested by shareholders. Neovasc's management efficiency ratios could be used to measure how well Neovasc manages its routine affairs as well as how well it operates its assets and liabilities.Neovasc Workforce Comparison
Neovasc is rated below average in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 26,002. Neovasc adds roughly 16.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Neovasc Notable Stakeholders
A Neovasc stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Neovasc often face trade-offs trying to please all of them. Neovasc's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Neovasc's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Fred Colen | President CEO | Profile | |
Alexei Marko | CEO and Non-Independent Director | Profile | |
Paul Geyer | Chairman of the Board | Profile | |
Brian McPherson | COO and President of Neovasc Surgical | Profile | |
Christopher Clark | CFO, Corporate Secretary | Profile | |
Steven Rubin | Independent Director | Profile | |
William ONeill | Independent Director | Profile | |
Douglas Janzen | Independent Director | Profile | |
Jane Hsiao | Independent Director | Profile | |
Vicki Bebeau | VP of Clinical Affairs | Profile | |
Randy Lane | VP of RandD | Profile | |
BA BA | CFO Sec | Profile | |
Sarah Gallagher | VP Affairs | Profile | |
Fredericus Colen | CEO Pres | Profile | |
John Panton | Chief Officer | Profile | |
William Little | Chief Officer | Profile |
About Neovasc Management Performance
The success or failure of an entity such as Neovasc often depends on how effective the management is. Neovasc management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Neovasc management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Neovasc management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada. Neovasc operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 49 people.
The data published in Neovasc's official financial statements usually reflect Neovasc's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Neovasc. For example, before you start analyzing numbers published by Neovasc accountants, it's critical to develop an understanding of what Neovasc's liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Neovasc's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neovasc's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Neovasc's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Neovasc. Please utilize our Beneish M Score to check the likelihood of Neovasc's management manipulating its earnings.
Neovasc Workforce Analysis
Traditionally, organizations such as Neovasc use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Neovasc within its industry.Neovasc Manpower Efficiency
Return on Neovasc Manpower
Revenue Per Employee | 237.8K | |
Revenue Per Executive | 237.8K | |
Net Loss Per Employee | 2.6M | |
Net Loss Per Executive | 2.6M | |
Working Capital Per Employee | 3.4M | |
Working Capital Per Executive | 3.4M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Neovasc information on this page should be used as a complementary analysis to other Neovasc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Neovasc Stock
If you are still planning to invest in Neovasc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neovasc's history and understand the potential risks before investing.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |